Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
BioStem Technologies (OTC: BSEM) logo — We Manufacture Products That Change Lives

BioStem Technologies (OTC: BSEM)

We Manufacture Products That Change Lives

Founded 2014 United States Pompano Beach, United States 47 employees Post Ipo Equity Total: $2.00M Biotechnology, Pharmaceutical

General Information

Company Name BioStem Technologies (OTC: BSEM)
Founded Year 2014
Location United States Pompano Beach, United States +1
Founders / Decision Makers
Team member
Employees 47
Industries Biotechnology, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when BioStem Technologies (OTC: BSEM) moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About BioStem Technologies (OTC: BSEM)

BioStem Technologies (OTC: BSEM) is a leading innovator in the biotechnology and pharmaceutical industries, specializing in the development, manufacture, and commercialization of allografts for regenerative therapies. The company's BioRetain processing method is at the core of its focus on manufacturing products that change lives, as it aims to maintain growth factors and preserve tissue structure. Notably, BioStem Technologies' quality management system and standard operating procedures have earned accreditation from the American Association of Tissue Banks (AATB), adhering to current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP). The company's portfolio of quality brands includes VENDAJE, VENDAJE AC, and VENDAJE OPTIC, with each placental allograft processed at the company's FDA registered and AATB accredited site in Pompano Beach, Florida. The company, established in 2015, recently secured a $2.00M Post-IPO Equity investment on 03 November 2023, signaling investor confidence in BioStem Technologies' trajectory. The absence of information regarding specific investors that participated in this latest funding round suggests an opportunity for further exploration of the company's investor base. As the company continues to pioneer advancements in regenerative medicine, its continued access to financial resources and strategic partnerships will be crucial in driving its mission of harnessing perinatal tissue's natural properties to develop transformative regenerative therapies.

Taxonomy: regenerative medicine, perinatal tissue, allografts, BioRetain processing, growth factors preservation, quality management, AATB accreditation, cGTP, cGMP, FDA registered, VENDAJE, placental allograft

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 03 Nov 2023

BioStem Technologies (OTC: BSEM) Alternatives & Competitors

BioStem Technologies (OTC: BSEM) vs
Surgical Biologics LLC
Surgical Biologics LLC

Surgical Biologics is the leader in the development and manufacture of placental-based allografts,...

4 employees
Biotechnology, Health Care
BioStem Technologies (OTC: BSEM) vs
Pinnacle Transplant Technologies
Pinnacle Transplant Technologies United States

Improve Today, Advance Tomorrow, Honor the Gift.

Series Unknown
112 employees
Biotechnology, Health Care
Compare BioStem Technologies (OTC: BSEM) vs Pinnacle Transplant Technologies
BioStem Technologies (OTC: BSEM) vs
Snoasis Medical, LLC
Snoasis Medical, LLC United States

Developing regenerative solutions for dental surgery, enhancing healing with state-of-the-art allogr...

Grant
8 employees
Health Care, Medical Devices
Compare BioStem Technologies (OTC: BSEM) vs Snoasis Medical, LLC
Also compare with: BioStem Technologies (OTC: BSEM) vs Lonza Netherlands, former PharmaCell Lonza Netherlands, former PharmaCell

FAQ About BioStem Technologies (OTC: BSEM)

We Manufacture Products That Change Lives
BioStem Technologies (OTC: BSEM) was founded in 2014.
BioStem Technologies (OTC: BSEM) is headquartered in Pompano Beach, United States.
BioStem Technologies (OTC: BSEM) operates in the following industries: Biotechnology, Pharmaceutical.
BioStem Technologies (OTC: BSEM) has approximately 47 employees.
BioStem Technologies (OTC: BSEM) has completed 1 funding round, raising a total of $2.00M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to BioStem Technologies (OTC: BSEM) include Surgical Biologics LLC, Pinnacle Transplant Technologies, Snoasis Medical, LLC, BioD, Lonza Netherlands, former PharmaCell. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BioStem Technologies (OTC: BSEM) and Surgical Biologics LLC are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors BioStem Technologies (OTC: BSEM) and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy